When Accelerated Approval Fails: FDA Withdrawal Trends and Strategic Lessons for Oncology Sponsors
The FDA Accelerated Approval (AA) pathway remains one of the most powerful regulatory mechanisms in oncology, enabling earlier...
07
Aug
16
Jul
The Missing Majority: Why Older Adults Remain the Weakest Link in Oncology Trial Evidence
Over the past decade, oncology has achieved a level of biological precision that would have been difficult to...
16
Jun
GLP-1 Receptor Agonists and Cancer: Separating Signal from Noise
The GLP-1 and cancer debate is increasingly being discussed not only as a safety question, but also as...
13
May
Precision Medicine From Biology to Bedside With Dr. Wafik El-Deiry
In the early 1990s, Wafik El-Deiry helped identify a gene that explained one of cancer biology’s most essential...
04
May
What it Takes to Lead at the Top: Dr. Lisa Butterfield on Leading through the...
There are moments in science when a single idea changes not only a line of research, but the...
30
Apr
Precision Oncology in the Space Between Data and Delivery: Dr. Benedikt Westphalen’s Vision for the...
A tumor can be sequenced in extraordinary detail and still leave the patient with no meaningful option. That...
20
Apr
Rethinking the myth of the “Dark Side” With Dr. Lokesh Jain
The transition from clinical practice or a research career to the pharmaceutical industry is often met with the...
14
Apr
What It Takes to Lead at the Top: Dr. Roy Baynes and the Discipline of...
There is one idea that seems to sit at the center of Dr. Roy Baynes’s career, and perhaps...
